Cover Image
市場調查報告書

梅毒檢驗的全球市場 (疾病形態,各地區) - 全球產業,分析,各國市場規模,佔有率,成長率,企業簡介,需求,考察,趨勢及預測:2014-2020年

Global Syphilis Testing Market (Types and Geography) - Global Industry Analysis, Country-Wise Market Size, Share, Growth, Company Profiles, Demand, Insights, Trends and Forecast, 2014 - 2020

出版商 Allied Market Research 商品編碼 332541
出版日期 內容資訊 英文 118 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
梅毒檢驗的全球市場 (疾病形態,各地區) - 全球產業,分析,各國市場規模,佔有率,成長率,企業簡介,需求,考察,趨勢及預測:2014-2020年 Global Syphilis Testing Market (Types and Geography) - Global Industry Analysis, Country-Wise Market Size, Share, Growth, Company Profiles, Demand, Insights, Trends and Forecast, 2014 - 2020
出版日期: 2015年05月01日 內容資訊: 英文 118 Pages
簡介

梅毒是由被稱為梅毒螺旋體的細菌所引起,具有致死可能的一種性病,一旦誤診將導致長期併發症。由於梅毒在雙性人及同性戀者間發病數大增,而一直是全球性健康問題。根據世界衛生組織(WHO)指出,全球整體病例數2013年時為3600萬件。每年都有1100萬件新的感染病例。梅毒檢驗的全球市場預計今後數年將以1.2%的年複合成長率擴大,到2020年達到36億5030萬美元規模。

本報告以梅毒檢驗的全球市場為焦點,依疾病形態及地區 (北美,歐洲,亞太地區,中南美·中東·非洲) 別分析·預測2014-2020年這段期間供需規模的轉變,並彙整市場發展的推動·阻礙因素,產業結構,競爭環境,主要加入企業等相關的最新資訊。

第1章 簡介

  • 報告內容
  • 報告的主要優點
  • 主要市場區隔
  • 調查方法
    • 二級資訊調查
    • 主要資訊調查採訪
    • 分析工具及模式

第2章 摘要整理

  • 高階主管的觀點
  • 今後到2025年的市場預測 (單位:100萬美元)
    • 穩定成長方案
    • 急速成長方案
    • 負成長方案

第3章 市場概要

  • 市場定義和範圍
  • 梅毒檢驗市場未來趨勢
    • 全球各國的確實針對申請資格認證全國檢驗計劃的實施
    • 梅毒診斷檢驗市場技術進步
  • 梅毒診斷檢驗
  • 重要發現
    • 梅毒診斷檢驗的全球市場最有力影響係數
    • 梅毒診斷檢驗全球市場的最有力投資口袋
    • 梅毒診斷檢驗全球市場的最有力成功策略
  • 行政法規和醫療報酬
    • 行政法規
    • 面向了梅毒檢驗的醫療報酬制度
  • 價值鏈分析
    • 主要活動
    • 支援活動
  • 市場動態
    • 推動要素
      • 梅毒發病率的上升和得病率的擴大
      • 實施全國規模的檢驗計劃
      • 支援梅毒檢驗的醫療報酬
    • 阻礙因素
      • 赴性病診療機關的患者受到社會性歧視
      • 偏遠地區的龐大梅毒感染者數
      • 針對打入梅毒市場企業的嚴格法規遵守之必要性
    • 機會
      • 泌尿生殖器診療機關和性病診療機關的顧客數正在減少
      • 全球性國家規模檢驗計劃
      • 新興市場上技術及就地檢驗供應商的間隙商機

第4章 梅毒檢驗的全球市場 - 不同疾病形態:2014-2020年

  • P&S梅毒檢驗 (數量及金額)
    • 重要市場趨勢
    • 市場規模及預測 (數量及金額)
  • 一次梅毒檢驗
  • 二次梅毒檢驗
    • 市場規模及預測

第5章 梅毒檢驗的全球市場 - 各地區:2014-2020年

  • 北美
    • 市場規模及預測 (數量及金額)
    • 美國
    • 墨西哥
    • 加拿大
  • 歐洲
    • 市場規模及預測 (數量及金額)
    • 西班牙
    • 希臘
    • 比利時
    • 德國
    • 摩爾多瓦
    • 英國
    • 其他歐洲各國
  • 亞太地區
    • 市場規模及預測 (數量及金額)
    • 印度
    • 中國
    • 日本
    • 澳洲
    • 其他亞太地區各國
  • 中南美,中東·非洲
    • 市場規模及預測 (數量及金額)
    • 中南美
    • 中東
    • 非洲

第6章 企業簡介 (企業概要,企業短評,支援事業領域,業績,SWOT分析等)

  • Roche Diagnostics
  • BioMerieux
  • Hologic, Inc.
  • Becton Dickinson And Company
  • Cepheid Inc.
  • Danaher Corporation
  • Affymetrix, Inc.
  • Alere Inc.
  • Abbott Laboratories
  • DiaSorin
目錄
Product Code: DI 15675

Syphilis is one of the vital sexually transmitted infections (STIs) caused by the bacteria named, Treponema pallidum, and can lead to long-term complications, if not diagnosed adequately. Syphilis continues to be a global health concern due to the increasing incidences occurring mainly among bisexuals, gays and MSM (men who have sex with men). According to the World Health Organization (WHO), there were an estimated 36 million cases of syphilis in 2013 globally, with over 11 million new cases occurring annually. Additionally, around 90% of the syphilis cases are prevalent in developing countries with similar trends now observed in developed nations as well. The increasing syphilis cases are mainly due to the growing rate of anonymous sex, sex with multiple partners, sex under the influence of several drugs and increasing number of unprotected sex both anal and oral. Moreover, this is also gaining prominence in pregnant women due to the sex with infected partners, which can further lead to congenital abnormalities such as stillbirth, abortions and other abnormalities in pregnancy.

The global syphilis testing market is expected to reach $3,650.3 million by 2020, at a CAGR of 1.2%, from 2014 to 2020. There are various methods used for diagnosing syphilis cases, which include venereal disease research laboratory (VDRL) test, rapid plasma reagin (RPR) test, enzyme immunoassay (EIA) test and few others. All syphilis tests are serological i.e. based upon antibodies present in the body fluid. The market would continue to grow primarily due to the rising incidences of fatal syphilis diseases, disease-related high-economic burden and concurrent implementation of new programs such as provider-initiated counselling and testing (PICT) and client-initiated counselling and testing (CICT). However, inadequate infrastructure provisions such as labs, equipment and supplies, lack of trained laboratory personnel in secluded geographic locations such as West African countries and the stigma associated with voluntary testing are likely to be some of the major restraints of the market.

The report segments the global syphilis testing market on the basis of type and geography. Based on type, the market is segment into primary and secondary syphilis testing. Geographically, the market is segmented into North America, Europe, Asia Pacific and LAMEA. LAMEA and Asia Pacific region account for majority of the syphilis testing market and collectively accounted for 4/5th share of the global market value in 2014. Higher adoption rates for technologically advanced screening tests, active measures from the governments and private associations along with the growing awareness for the syphilis infections largely contribute to growth of the market in the aforesaid regions. The major players in the syphilis testing market are focusing on technological advancements in developing syphilis testing products along with complementary service portfolios. Some of the key companies profiled in the report are Roche Diagnostics, Hologic, Inc., Becton Dickinson & Company, Abbott Laboratories, BioMerieux, Alere Inc., Cepheid Inc., Affymetrix, Inc. and Diasorin.

KEY MARKET BENEFITS:

This report provides an extensive analysis of the current and emerging market trends along with the market dynamics of the global Syphilis testing market

A comprehensive analysis of types and geography segments helps to identify the growth opportunities in the global syphilis testing market

Competitive intelligence (of leading manufacturers and distributors of leading syphilis testing devices and services) highlights the business practices followed by leading market players across the geographies

The projections in the report are made by analyzing the current market trends and market potential for the period of 2014-2020, in terms of value and volume

SWOT analysis enables to study the internal environment of the leading companies for strategy formulation

KEY MARKET SEGMENTS:

  • The global syphilis testing market is segmented into types and geography.
    • The Global Syphilis Testing Market - By Types
    • Primary Syphilis
    • Secondary Syphilis
  • The Global Syphilis Testing Market - By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • U.K.
      • Germany
      • Spain
      • Greece
      • Belgium
      • Moldova
      • Rest of Europe
    • Asia-Pacific
      • Australia
      • Japan
      • India
      • China
      • Rest of Asia Pacific
    • LAMEA
      • Latin America
      • Middle East
      • Africa

Table of Contents

CHAPTER 1 - INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits
  • 1.3. Key market segments
  • 1.1. Research methodology
    • 1.1.1. Secondary research
    • 1.1.2. Primary research
    • 1.1.3. Analyst tools and models

CHAPTER 2 - EXECUTIVE SUMMARY

  • 2.1. CXO perspective
  • 2.2. Market beyond what to expect by 2025($Million)
    • 2.2.1. Moderate growth scenario
    • 2.2.2. Rapid growth scenario
    • 2.2.3. Diminishing growth scenario

CHAPTER 3 - MARKET OVERVIEW

  • 3.1. Market Definition and Scope
  • 3.2. Upcoming trends for Syphilis diagnostic testing market
    • 3.2.1. Executing and ensuring accreditation for the qualification of participants in National Screening Programs around the globe.
    • 3.2.2. Technological Advancements for Syphilis diagnostic testing market
  • 3.3. Syphilis diagnostic tests
  • 3.4. Key Findings
    • 3.4.1. Top Factors Impacting global Syphilis diagnostic testing market
    • 3.4.2. Top Investment Pockets of global Syphilis diagnostic testing market (2014-2020)
    • 3.4.3. Top winning strategies of global Syphilis diagnostic testing market
  • 3.5. Government Regulations and reimbursement scenario
    • 3.5.1. Government Regulation
    • 3.5.2. Reimbursement policies for Syphilis testing
  • 3.6. Value Chain Analysis
    • 3.6.1. Primary Activities
    • 3.6.2. Supportive Activities
  • 3.7. Market dynamics
    • 3.7.1. Drivers
      • 3.7.1.1. Growing incidence rates and increasing prevalence rates of Syphilis
      • 3.7.1.2. Implementation of National Screening Programs
      • 3.7.1.3. Supporting Reimbursement for Syphilis testing
    • 3.7.2. Restraints
      • 3.7.2.1. Social stigma associated with patients visiting specialized STD clinics.
      • 3.7.2.2. Huge proportion of patients infected with Syphilis in remote areas.
      • 3.7.2.3. Stringent regulatory abidance requirements for the participants of Syphilis market
    • 3.7.3. Opportunities
      • 3.7.3.1. Decreasing number of visits to GUM clinics and specialized STD clinics
      • 3.7.3.2. National screening Programs across the globe
      • 3.7.3.3. Niche opportunities for technology and POC test providers in an emerging economies

CHAPTER 4 - GLOBAL SYPHILIS TESTING MARKET, BY TYPE, 2014-2020

  • 4.1. P&S Syphilis testing (volume and value)
    • 4.1.1. Key market trends
    • 4.1.2. Market size and forecast, (volume & value)
      • 4.1.2.1. Global Testing Market for Syphilis,value, ($million)
      • 4.1.2.2. Global Testing Market for Syphilis, volume, (million)
  • 4.2. Primary Syphilis
  • 4.3. Secondary Syphilis
    • 4.3.1. Market size and forecast, (volume & value)

CHAPTER 5 - GLOBAL SYPHILIS TESTING MARKET, BY GEOGRAPHY, 2014-2020

  • 5.1. North America
    • 5.1.1. Market size and forecast, (volume & value)
    • 5.1.2. U.S.
      • 5.1.2.1. Market size and forecast (Volume & Value)
    • 5.1.3. Mexico
      • 5.1.3.1. Market size and forecast, (volume & value)
    • 5.1.4. Canada
      • 5.1.4.1. Market size and forecast, (volume & value)
  • 5.2. Europe
    • 5.2.1. Market size and forecast, (volume & value)
    • 5.2.2. Spain
      • 5.2.2.1. Market size and forecast, (volume & value)
    • 5.2.3. Greece
      • 5.2.3.1. Market size and forecast, (volume & value)
    • 5.2.4. Belgium
      • 5.2.4.1. Market size and forecast, (volume & value)
    • 5.2.5. Germany
      • 5.2.5.1. Market size and forecast, (volume & value)
    • 5.2.6. Moldova
      • 5.2.6.1. Market size and forecast, (volume & value)
    • 5.2.7. United Kingdom
      • 5.2.7.1. Market size and forecast, (volume & value)
    • 5.2.8. Rest of Europe
      • 5.2.8.1. Market size and forecast, (volume & value)
  • 5.3. Asia Pacific
    • 5.3.1. Market size and forecast, (volume & value)
    • 5.3.2. India
      • 5.3.2.1. Market size and forecast, (volume & value)
    • 5.3.3. China
      • 5.3.3.1. Market size and forecast, (volume & value)
    • 5.3.4. Japan
      • 5.3.4.1. Market size and forecast, (volume & value)
    • 5.3.5. Australia
      • 5.3.5.1. Market size and forecast, (volume & value)
    • 5.3.6. Rest of Asia-Pacific
      • 5.3.6.1. Market size and forecast, (volume & value)
  • 5.4. LAMEA
    • 5.4.1. Market size and forecast, (volume & value)
    • 5.4.2. Latin America
      • 5.4.2.1. Market size and forecast, (volume & value)
      • 5.4.2.2. Argentina
        • 5.4.2.2.1. MARKET SIZE AND FORECAST, (VOLUME & VALUE)
    • 5.4.3. Middle East
      • 5.4.3.1. Market size and forecast, (volume & value)
    • 5.4.4. Africa
      • 5.4.4.1. Market size and forecast, (volume & value)

CHAPTER 6 - COMPANY PROFILES

  • 6.1. Roche Diagnostics
    • 6.1.1. Company overview
    • 6.1.2. Roche Diagnostics company snapshot
    • 6.1.3. Operating business segments
    • 6.1.4. Financial performance
    • 6.1.5. Strategic moves and developments
    • 6.1.6. SWOT analysis Roche Diagnostics
  • 6.2. BioMerieux
    • 6.2.1. Company overview
    • 6.2.2. Biomerieux Company Snapshot
    • 6.2.3. Operating business segments
    • 6.2.4. Business performance
    • 6.2.5. SWOT analysis of BioMerieux
  • 6.3. Hologic, Inc.
    • 6.3.1. Company overview
    • 6.3.2. Hologic, Inc. Company Snapshot
    • 6.3.3. Operating business segments
    • 6.3.4. Financial performance
    • 6.3.5. Strategic moves and developments
    • 6.3.6. SWOT analysis of Hologic Inc
  • 6.4. Becton Dickinson And Company
    • 6.4.1. Company overview
    • 6.4.2. Becton Dickinson And Company Snapshot
    • 6.4.3. Operating Business Segments
    • 6.4.4. Business performance
    • 6.4.5. Key Strategies and development
    • 6.4.6. SWOT analysis of Becton Dickinson and Company
  • 6.5. Cepheid Inc.
    • 6.5.1. Company overview
    • 6.5.2. Cephide Inc. company snapshot
    • 6.5.3. Operating Business Segments
    • 6.5.4. Financial performance
    • 6.5.5. Strategic moves and developments
    • 6.5.6. SWOT analysis of Cepheid Inc.
  • 6.6. Danaher Corporation
    • 6.6.1. Company overview
    • 6.6.2. Danaher Corporation Company Snapshot
    • 6.6.3. Operating business segments
    • 6.6.4. Business performance
    • 6.6.5. Key Strategies and development
    • 6.6.6. SWOT analysis of Danaher Corporation
  • 6.7. Affymetrix, Inc.
    • 6.7.1. Company overview
    • 6.7.2. Affymetrix Inc. Company Snapshot
    • 6.7.3. Operating. business segments
    • 6.7.4. Financial performance
    • 6.7.5. SWOT analysis of Affymetrix Inc
  • 6.8. Alere Inc.
    • 6.8.1. Company overview
    • 6.8.2. Alere Inc. Company Snapshot
    • 6.8.3. Operating business segments
    • 6.8.4. Business performance
    • 6.8.5. Key Strategies and developments
    • 6.8.6. SWOT analysis of Alere Inc.
  • 6.9. Abbott Laboratories
    • 6.9.1. Company overview
    • 6.9.2. Abbott Laboratories company snapshot
    • 6.9.3. Operating business segments
    • 6.9.4. Financial performance
    • 6.9.5. Strategic moves and developments
    • 6.9.6. SWOT analysis of Abbott Laboratories
  • 6.10. DiaSorin
    • 6.10.1. Company overview
    • 6.10.2. DiaSorin Company Snapshot
    • 6.10.3. Operating business segments
    • 6.10.4. Financial performance
    • 6.10.5. Strategic moves and developments
    • 6.10.6. SWOT analysis of DiaSorin

List of Tables

  • TABLE 1: GLOBAL SYPHILIS TESTING MARKET, MODERATE GROWTH SCENARIO, BY GEOGRAPHY, VALUE ($MILLION), 2020-2025
  • TABLE 2: GLOBAL SYPHILIS TESTING MARKET, MODERATE GROWTH SCENARIO, BY GEOGRAPHY, VOLUME (MILLION), 2020-2025
  • TABLE 3: GLOBAL SYPHILIS TESTING MARKET, RAPID GROWTH SCENARIO, BY GEOGRAPHY, VALUE ($MILLION), 2020-2025
  • TABLE 4: GLOBAL SYPHILIS TESTING MARKET, RAPID GROWTH SCENARIO, BY GEOGRAPHY, VOLUME (MILLION), 2020-2025
  • TABLE 5: GLOBAL SYPHILIS TESTING MARKET, DIMINISHING GROWTH SCENARIO, BY GEOGRAPHY, VALUE ($MILLION), 2020-2025
  • TABLE 6: GLOBAL SYPHILIS TESTING MARKET, DIMINISHING GROWTH SCENARIO, BY GEOGRAPHY, VOLUME (MILLION), 2020-2025
  • TABLE 7: SYPHILIS PREVENTIVE SERVICES BY CDC
  • TABLE 8: GLOBAL SYPHILIS TESTING MARKET VALUE, BY GEOGRAPHY, 2014-2020 ($MILLION)
  • TABLE 9: GLOBAL SYPHILIS TESTING MARKET VOLUME, BY GEOGRAPHY, 2014-2020 (MILLION)
  • TABLE 10: GLOBAL SYPHILIS TESTING MARKET BY TYPES, VALUE ($MILLION), 2014-2020
  • TABLE 11: GLOBAL SYPHILIS TESTING MARKET BY TYPES, VOLUME (MILLION), 2014-2020
  • TABLE 12: GLOBAL SYPHILIS TESTING MARKET, BY GEOGRAPHY, 2014-2020, VALUE ($MILLION)
  • TABLE 13: GLOBAL SYPHILIS TESTING MARKET, BY GEOGRAPHY, 2014-2020, VOLUME (MILLION)
  • TABLE 14: NORTH AMERICA SYPHILIS TESTING MARKET, VALUE ($MILLION), 2014-2020
  • TABLE 15: NORTH AMERICA SYPHILIS TESTING MARKET, VOLUME (MILLION), 2014-2020
  • TABLE 16: U.S. SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 17: MEXICO SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 18: CANADA SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 19: EUROPE SYPHILIS TESTING MARKET, VALUE ($MILLION), 2014-2020
  • TABLE 20: EUROPE SYPHILIS TESTING MARKET, VOLUME (MILLION), 2014-2020
  • TABLE 21: SPAIN SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 22: GREECE SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 23: BELGIUM SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 24: GERMANY SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 25: MOLDOVA SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 26: UNITED KINGDOM SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 27: REST OF EUROPE SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 28: ASIA PACIFIC SYPHILIS TESTING MARKET, VALUE ($MILLION), 2014-2020
  • TABLE 29: ASIA PACIFIC SYPHILIS TESTING MARKET, VOLUME (MILLION), 2014-2020
  • TABLE 30: INDIA SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 31: CHINA SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 32: JAPAN SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 33: AUSTRALIA SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 34: OTHERS ASIA PACIFIC SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 35: LAMEA SYPHILIS TESTING MARKET, VALUE, ($MILLION), 2014-2020
  • TABLE 36: LAMEA SYPHILIS TESTING MARKET, VOLUME (MILLION), 2014-2020
  • TABLE 37: LATIN AMERICA SYPHILIS TESTING MARKET, VALUE ($MILLION), 2014-2020
  • TABLE 38: LATIN AMERICA SYPHILIS TESTING MARKET, VOLUME (MILLION), 2014-2020
  • TABLE 39: ARGENTINA SYPHILIS TESTING MARKET , VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 40: MIDDLE EAST SYPHILIS TESTING MARKET, VALUE ($MILLION) AND VOLUME (MILLION), 2014-2020
  • TABLE 41: AFRICA SYPHILIS TESTING MARKET, VALUE ($MILLION), 2014-2020
  • TABLE 42: AFRICA SYPHILIS TESTING MARKET, VOLUME (MILLION), 2014-2020
  • TABLE 43: ROCHE DIAGNOSTICS COMPANY SNAPSHOT
  • TABLE 44: ROCHE DIAGNOSTICS OPERATING SEGMENTS
  • TABLE 45: BIOMERIEUX COMPANY SNAPSHOT
  • TABLE 46: BIOMERIEUX OPERATING SEGMENTS
  • TABLE 47: HOLOGIC, INC. COMPANY SNAPSHOT
  • TABLE 48: HOLOGIC, INC. OPERATING SEGMENTS
  • TABLE 49: BECTON DICKINSON AND COMPANY SNAPSHOT
  • TABLE 50: BECTON DICKINSON AND COMPANY OPERATING SEGMENTS
  • TABLE 51: CEPHIDE INC COMPANY SNAPSHOT
  • TABLE 52: CEPHEID INC. OPERATING SEGMENTS
  • TABLE 53: DANAHER CORPORATION COMPANY SNAPSHOT
  • TABLE 54: DANAHER CORPORATION OPERATING SEGMENTS
  • TABLE 55: AFFYMETRIX INC. COMPANY SNAPSHOT
  • TABLE 56: AFFYMETRIX, INC. OPERATING SEGMENTS
  • TABLE 57: ALERE INC. COMPANY SNAPSHOT
  • TABLE 58: ALERE INC. OPERATING SEGMENTS
  • TABLE 59: ABBOTT LABORATORIES COMPANY SNAPSHOT
  • TABLE 60: ABBOTT LABORATORIES OPERATING SEGMENTS
  • TABLE 61: DIASORIN COMPANY SNAPSHOT
  • TABLE 62: DIASORIN OPERATING SEGMENTS

List of Figures

  • FIG. 1: IMPACT ANALYSIS OF MODERATE GROWTH SCENARIO (2020-2025)
  • FIG. 2: IMFPACT ANALYSIS OF RAPID GROWTH SCENARIO (2020-2025)
  • FIG. 3: IMPACT ANALYSIS OF DIMINISHING GROWTH SCENARIO (2020-2025)
  • FIG. 4: TOP FACTORS IMPACTING GLOBAL SYPHILIS TESTING MARKET, 2014-2020
  • FIG. 5: TOP INVESTMENT POCKETS OF GLOBAL SYPHILIS TESTING MARKET (2014-2020)
  • FIG. 6: TOP WINING STRATEGIES IN GLOBAL SYPHILIS TESTING MARKET (2011-2014)
  • FIG. 7: VALUE CHAIN ANALYSIS OF GLOBAL SYPHILIS TESTING MARKET
  • FIG. 8: SYPHILIS INCIDENCE IN MEXICO (2009-2013)
  • FIG. 9: SYPHILIS INCIDENCE RATE IN MEXICO (2009-2013)
  • FIG. 10: KEY FINANCIALS OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2014)
  • FIG. 11: SWOT ANALYSIS OF ROCHE DIAGNOSTICS
  • FIG. 12: KEY FINANCIALS OF BIOMERIEUX BY APPLICATIONS (2013)
  • FIG. 13: KEY FINANCIALS OF BIOMERIEUX BY GEOGRAPHY (2013)
  • FIG. 14: SWOT ANALYSIS OF BIOMERIEUX
  • FIG. 15: KEY FINANCIALS OF HOLOGIC, INC. BY OPERATING SEGMENTS(2012)
  • FIG. 16: KEY FINANCIALS OF HOLOGIC, INC. BY GEOGRAPHY (2012)
  • FIG. 17: SWOT ANALYSIS OF HOLOGIC, INC.
  • FIG. 18: KEY FINANCIALS OF BECTON DICKINSON AND COMPANY BY SEGMENT (2013)
  • FIG. 19: KEY FINANCIALS OF BECTON DICKINSON AND COMPANY BY GEOGRAPHY (2013)
  • FIG. 20: SWOT ANALYSIS OF BECTON DICKINSON AND COMPANY
  • FIG. 21: KEY FINANCIALS OF CEPHEID INC. BY GEOGRAPHY(2013)
  • FIG. 22: KEY FINANCIALS OF CEPHEID INC. BY CLINICAL AND NON CLINICAL MARKET(2013)
  • FIG. 23: SWOT ANALYSIS OF CEPHEID INC.
  • FIG. 24: KEY FINANCIALS OF DANAHER CORPORATION BY OPERATING (SEGMENT) 2013
  • FIG. 25: KEY FINANCIALS OF DANAHER CORPORATION BY GEOGRAPHY (2013)
  • FIG. 26: SWOT ANALYSIS OF DANAHER CORPORATION
  • FIG. 27: KEY FINANCIALS OF AFFYMETRIX, INC. BY OPERATING SEGMENTS (2013)
  • FIG. 28: KEY FINANCIALS OF AFFYMETRIX, INC. BY GEOGRAPHY (2013)
  • FIG. 29: SWOT ANALYSIS OF AFFYMETRIX INC.
  • FIG. 30: KEY FINANCIALS OF ALERE INC. BY THERAPEUTICS (2013)
  • FIG. 31: KEY FINANCIALS OF ALERE INC. BY GEOGRAPHY (2013)
  • FIG. 32: SWOT ANALYSIS OF ALERE INC.
  • FIG. 33: KEY FINANCIALS OF ABBOTT LABORATORIES BY OPERATING SEGMENTS (2013)
  • FIG. 34: SWOT ANALYSIS OF ABBOTT LABORATORIES
  • FIG. 35: KEY FINANCIALS OF DIASORIN BY TECHNOLOGY (2013)
  • FIG. 36: KEY FINANCIALS OF DIASORIN BY GEOGRAPHY (2013)
  • FIG. 37: SWOT ANALYSIS OF DIASORIN
Back to Top